Open-House-Biologika-Rabattverträge 2026-11 - Infliximab (Darreichungsform zur intravenösen Anwendung)

Summary

The tender concerns an open-house medicinal product rebate agreement for infliximab for intravenous use. The contracting authorities intend to conclude contracts with all suitable pharmaceutical undertakings on uniform terms, without individual negotiations and without exclusivity. The contract term runs until 31 May 2028, and accession is possible at any time during the contract period. The bidder must be a pharmaceutical undertaking and must be able to show that it is entitled to place the relevant medicinal products on the market.